IBD Serology and Disease Outcomes in African Americans with Crohn's Disease

Madeline Bertha, Arthi Vasantharoopan, Archana Kumar, Beau B. Bruce, Jarod Prince, Tatyana Hofmekler, David Okou, Pankaj Chopra, Gabriel Wang, Cary Sauer, Carol J. Landers, Sunny Z. Hussain, Raymond K. Cross, Robert N. Baldassano, Michael D. Kappelman, Jeffrey Katz, Jonathan S. Alexander, Barbara S. Kirschner, Dedrick E. Moulton, Bankole O. OsuntokunAshish S Patel, Shehzad Saeed, Jan Michael A. Klapproth, Tanvi A. Dhere, Marla C. Dubinsky, Dermot McGovern, Subra Kugathasan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Backgrounds: Recent studies have identified the role of serologic markers in characterizing disease phenotype, location, complications, and severity among Northern Europeans (NE) with Crohn's disease (CD). However, very little is known about the role of serology in CD among African Americans (AA). Our study explored the relationship between serology and disease phenotype in AA with CD, while controlling for genetic ancestry. Methods: AAs with CD were enrolled as participants through multicenter collaborative efforts. Serological levels of IgA anti-Saccharomyces cervisiae antibody (ASCA), IgG ASCA, E. coli outermembrane porin C, anti-CBir1, and ANCA were measured using enzyme-linked immunosorbent assays. Genotyping was performed using Illumina immunochip technology; an admixture rate was calculated for each subject. Multiple imputation by chained equations was performed to account for data missing at random. Logistic regression was used to calculate adjusted odds ratio (OR) for associations between serological markers and both complicated disease and disease requiring surgery. Results: A total of 358 patients were included in the analysis. The majority of our patients had inflammatory, noncomplicated disease (58.4%), perianal disease (55.7%), and documented colonic inflammation (86.8%). On multivariable analysis, both IgG ASCA and OmpC were associated with complicated disease (OR, 2.67; 95% CI, 1.67-4.28; OR, 2.23; 95% CI, 1.41-3.53, respectively) and disease requiring surgery (OR, 2.51; 95% CI, 1.49-4.22; OR, 3.57; 95% CI, 2.12-6.00). NE admixture to the African genome did not have any associations or interactions in relation to clinical outcome. Conclusions: Our study comprises the largest cohort of AAs with CD. The utility of serological markers for the prognosis of CD in NE applies equally to AA populations.

Original languageEnglish (US)
Pages (from-to)209-216
Number of pages8
JournalInflammatory Bowel Diseases
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Serology
Crohn Disease
African Americans
Odds Ratio
Saccharomyces
Phenotype
Porins
Antineutrophil Cytoplasmic Antibodies
Antibodies
Anti-Idiotypic Antibodies
Logistic Models
Enzyme-Linked Immunosorbent Assay
Genome
Escherichia coli
Inflammation
Technology
Population

Keywords

  • African Americans
  • Crohn's disease
  • inflammatory bowel disease
  • serology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Bertha, M., Vasantharoopan, A., Kumar, A., Bruce, B. B., Prince, J., Hofmekler, T., ... Kugathasan, S. (2018). IBD Serology and Disease Outcomes in African Americans with Crohn's Disease. Inflammatory Bowel Diseases, 24(1), 209-216. https://doi.org/10.1093/ibd/izx021

IBD Serology and Disease Outcomes in African Americans with Crohn's Disease. / Bertha, Madeline; Vasantharoopan, Arthi; Kumar, Archana; Bruce, Beau B.; Prince, Jarod; Hofmekler, Tatyana; Okou, David; Chopra, Pankaj; Wang, Gabriel; Sauer, Cary; Landers, Carol J.; Hussain, Sunny Z.; Cross, Raymond K.; Baldassano, Robert N.; Kappelman, Michael D.; Katz, Jeffrey; Alexander, Jonathan S.; Kirschner, Barbara S.; Moulton, Dedrick E.; Osuntokun, Bankole O.; Patel, Ashish S; Saeed, Shehzad; Klapproth, Jan Michael A.; Dhere, Tanvi A.; Dubinsky, Marla C.; McGovern, Dermot; Kugathasan, Subra.

In: Inflammatory Bowel Diseases, Vol. 24, No. 1, 01.01.2018, p. 209-216.

Research output: Contribution to journalArticle

Bertha, M, Vasantharoopan, A, Kumar, A, Bruce, BB, Prince, J, Hofmekler, T, Okou, D, Chopra, P, Wang, G, Sauer, C, Landers, CJ, Hussain, SZ, Cross, RK, Baldassano, RN, Kappelman, MD, Katz, J, Alexander, JS, Kirschner, BS, Moulton, DE, Osuntokun, BO, Patel, AS, Saeed, S, Klapproth, JMA, Dhere, TA, Dubinsky, MC, McGovern, D & Kugathasan, S 2018, 'IBD Serology and Disease Outcomes in African Americans with Crohn's Disease', Inflammatory Bowel Diseases, vol. 24, no. 1, pp. 209-216. https://doi.org/10.1093/ibd/izx021
Bertha M, Vasantharoopan A, Kumar A, Bruce BB, Prince J, Hofmekler T et al. IBD Serology and Disease Outcomes in African Americans with Crohn's Disease. Inflammatory Bowel Diseases. 2018 Jan 1;24(1):209-216. https://doi.org/10.1093/ibd/izx021
Bertha, Madeline ; Vasantharoopan, Arthi ; Kumar, Archana ; Bruce, Beau B. ; Prince, Jarod ; Hofmekler, Tatyana ; Okou, David ; Chopra, Pankaj ; Wang, Gabriel ; Sauer, Cary ; Landers, Carol J. ; Hussain, Sunny Z. ; Cross, Raymond K. ; Baldassano, Robert N. ; Kappelman, Michael D. ; Katz, Jeffrey ; Alexander, Jonathan S. ; Kirschner, Barbara S. ; Moulton, Dedrick E. ; Osuntokun, Bankole O. ; Patel, Ashish S ; Saeed, Shehzad ; Klapproth, Jan Michael A. ; Dhere, Tanvi A. ; Dubinsky, Marla C. ; McGovern, Dermot ; Kugathasan, Subra. / IBD Serology and Disease Outcomes in African Americans with Crohn's Disease. In: Inflammatory Bowel Diseases. 2018 ; Vol. 24, No. 1. pp. 209-216.
@article{4c83d0d47b30477cba4e3df733e5ac5e,
title = "IBD Serology and Disease Outcomes in African Americans with Crohn's Disease",
abstract = "Backgrounds: Recent studies have identified the role of serologic markers in characterizing disease phenotype, location, complications, and severity among Northern Europeans (NE) with Crohn's disease (CD). However, very little is known about the role of serology in CD among African Americans (AA). Our study explored the relationship between serology and disease phenotype in AA with CD, while controlling for genetic ancestry. Methods: AAs with CD were enrolled as participants through multicenter collaborative efforts. Serological levels of IgA anti-Saccharomyces cervisiae antibody (ASCA), IgG ASCA, E. coli outermembrane porin C, anti-CBir1, and ANCA were measured using enzyme-linked immunosorbent assays. Genotyping was performed using Illumina immunochip technology; an admixture rate was calculated for each subject. Multiple imputation by chained equations was performed to account for data missing at random. Logistic regression was used to calculate adjusted odds ratio (OR) for associations between serological markers and both complicated disease and disease requiring surgery. Results: A total of 358 patients were included in the analysis. The majority of our patients had inflammatory, noncomplicated disease (58.4{\%}), perianal disease (55.7{\%}), and documented colonic inflammation (86.8{\%}). On multivariable analysis, both IgG ASCA and OmpC were associated with complicated disease (OR, 2.67; 95{\%} CI, 1.67-4.28; OR, 2.23; 95{\%} CI, 1.41-3.53, respectively) and disease requiring surgery (OR, 2.51; 95{\%} CI, 1.49-4.22; OR, 3.57; 95{\%} CI, 2.12-6.00). NE admixture to the African genome did not have any associations or interactions in relation to clinical outcome. Conclusions: Our study comprises the largest cohort of AAs with CD. The utility of serological markers for the prognosis of CD in NE applies equally to AA populations.",
keywords = "African Americans, Crohn's disease, inflammatory bowel disease, serology",
author = "Madeline Bertha and Arthi Vasantharoopan and Archana Kumar and Bruce, {Beau B.} and Jarod Prince and Tatyana Hofmekler and David Okou and Pankaj Chopra and Gabriel Wang and Cary Sauer and Landers, {Carol J.} and Hussain, {Sunny Z.} and Cross, {Raymond K.} and Baldassano, {Robert N.} and Kappelman, {Michael D.} and Jeffrey Katz and Alexander, {Jonathan S.} and Kirschner, {Barbara S.} and Moulton, {Dedrick E.} and Osuntokun, {Bankole O.} and Patel, {Ashish S} and Shehzad Saeed and Klapproth, {Jan Michael A.} and Dhere, {Tanvi A.} and Dubinsky, {Marla C.} and Dermot McGovern and Subra Kugathasan",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/ibd/izx021",
language = "English (US)",
volume = "24",
pages = "209--216",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - IBD Serology and Disease Outcomes in African Americans with Crohn's Disease

AU - Bertha, Madeline

AU - Vasantharoopan, Arthi

AU - Kumar, Archana

AU - Bruce, Beau B.

AU - Prince, Jarod

AU - Hofmekler, Tatyana

AU - Okou, David

AU - Chopra, Pankaj

AU - Wang, Gabriel

AU - Sauer, Cary

AU - Landers, Carol J.

AU - Hussain, Sunny Z.

AU - Cross, Raymond K.

AU - Baldassano, Robert N.

AU - Kappelman, Michael D.

AU - Katz, Jeffrey

AU - Alexander, Jonathan S.

AU - Kirschner, Barbara S.

AU - Moulton, Dedrick E.

AU - Osuntokun, Bankole O.

AU - Patel, Ashish S

AU - Saeed, Shehzad

AU - Klapproth, Jan Michael A.

AU - Dhere, Tanvi A.

AU - Dubinsky, Marla C.

AU - McGovern, Dermot

AU - Kugathasan, Subra

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Backgrounds: Recent studies have identified the role of serologic markers in characterizing disease phenotype, location, complications, and severity among Northern Europeans (NE) with Crohn's disease (CD). However, very little is known about the role of serology in CD among African Americans (AA). Our study explored the relationship between serology and disease phenotype in AA with CD, while controlling for genetic ancestry. Methods: AAs with CD were enrolled as participants through multicenter collaborative efforts. Serological levels of IgA anti-Saccharomyces cervisiae antibody (ASCA), IgG ASCA, E. coli outermembrane porin C, anti-CBir1, and ANCA were measured using enzyme-linked immunosorbent assays. Genotyping was performed using Illumina immunochip technology; an admixture rate was calculated for each subject. Multiple imputation by chained equations was performed to account for data missing at random. Logistic regression was used to calculate adjusted odds ratio (OR) for associations between serological markers and both complicated disease and disease requiring surgery. Results: A total of 358 patients were included in the analysis. The majority of our patients had inflammatory, noncomplicated disease (58.4%), perianal disease (55.7%), and documented colonic inflammation (86.8%). On multivariable analysis, both IgG ASCA and OmpC were associated with complicated disease (OR, 2.67; 95% CI, 1.67-4.28; OR, 2.23; 95% CI, 1.41-3.53, respectively) and disease requiring surgery (OR, 2.51; 95% CI, 1.49-4.22; OR, 3.57; 95% CI, 2.12-6.00). NE admixture to the African genome did not have any associations or interactions in relation to clinical outcome. Conclusions: Our study comprises the largest cohort of AAs with CD. The utility of serological markers for the prognosis of CD in NE applies equally to AA populations.

AB - Backgrounds: Recent studies have identified the role of serologic markers in characterizing disease phenotype, location, complications, and severity among Northern Europeans (NE) with Crohn's disease (CD). However, very little is known about the role of serology in CD among African Americans (AA). Our study explored the relationship between serology and disease phenotype in AA with CD, while controlling for genetic ancestry. Methods: AAs with CD were enrolled as participants through multicenter collaborative efforts. Serological levels of IgA anti-Saccharomyces cervisiae antibody (ASCA), IgG ASCA, E. coli outermembrane porin C, anti-CBir1, and ANCA were measured using enzyme-linked immunosorbent assays. Genotyping was performed using Illumina immunochip technology; an admixture rate was calculated for each subject. Multiple imputation by chained equations was performed to account for data missing at random. Logistic regression was used to calculate adjusted odds ratio (OR) for associations between serological markers and both complicated disease and disease requiring surgery. Results: A total of 358 patients were included in the analysis. The majority of our patients had inflammatory, noncomplicated disease (58.4%), perianal disease (55.7%), and documented colonic inflammation (86.8%). On multivariable analysis, both IgG ASCA and OmpC were associated with complicated disease (OR, 2.67; 95% CI, 1.67-4.28; OR, 2.23; 95% CI, 1.41-3.53, respectively) and disease requiring surgery (OR, 2.51; 95% CI, 1.49-4.22; OR, 3.57; 95% CI, 2.12-6.00). NE admixture to the African genome did not have any associations or interactions in relation to clinical outcome. Conclusions: Our study comprises the largest cohort of AAs with CD. The utility of serological markers for the prognosis of CD in NE applies equally to AA populations.

KW - African Americans

KW - Crohn's disease

KW - inflammatory bowel disease

KW - serology

UR - http://www.scopus.com/inward/record.url?scp=85051411573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051411573&partnerID=8YFLogxK

U2 - 10.1093/ibd/izx021

DO - 10.1093/ibd/izx021

M3 - Article

C2 - 29272484

AN - SCOPUS:85051411573

VL - 24

SP - 209

EP - 216

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -